Dr. Reddy’s Laboratories (NYSE:RDY – Get Free Report) and Tvardi Therapeutics (NASDAQ:TVRD – Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation and risk.
Volatility and Risk
Dr. Reddy’s Laboratories has a beta of 0.31, suggesting that its share price is 69% less volatile than the S&P 500. Comparatively, Tvardi Therapeutics has a beta of 0.37, suggesting that its share price is 63% less volatile than the S&P 500.
Earnings & Valuation
This table compares Dr. Reddy’s Laboratories and Tvardi Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Dr. Reddy’s Laboratories | $3.58 billion | 3.45 | $456.00 million | $0.37 | 40.04 |
| Tvardi Therapeutics | $7.14 million | 2.50 | -$18.21 million | ($2.79) | -0.48 |
Dr. Reddy’s Laboratories has higher revenue and earnings than Tvardi Therapeutics. Tvardi Therapeutics is trading at a lower price-to-earnings ratio than Dr. Reddy’s Laboratories, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
3.8% of Dr. Reddy’s Laboratories shares are owned by institutional investors. Comparatively, 44.7% of Tvardi Therapeutics shares are owned by institutional investors. 2.0% of Dr. Reddy’s Laboratories shares are owned by insiders. Comparatively, 7.4% of Tvardi Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Profitability
This table compares Dr. Reddy’s Laboratories and Tvardi Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Dr. Reddy’s Laboratories | 8.56% | 7.91% | 5.29% |
| Tvardi Therapeutics | N/A | -145.40% | -91.11% |
Analyst Ratings
This is a summary of recent ratings and price targets for Dr. Reddy’s Laboratories and Tvardi Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Dr. Reddy’s Laboratories | 1 | 3 | 2 | 0 | 2.17 |
| Tvardi Therapeutics | 1 | 0 | 6 | 1 | 2.88 |
Dr. Reddy’s Laboratories presently has a consensus target price of $492.90, suggesting a potential upside of 3,227.03%. Tvardi Therapeutics has a consensus target price of $9.40, suggesting a potential upside of 601.49%. Given Dr. Reddy’s Laboratories’ higher possible upside, equities research analysts plainly believe Dr. Reddy’s Laboratories is more favorable than Tvardi Therapeutics.
Summary
Dr. Reddy’s Laboratories beats Tvardi Therapeutics on 8 of the 14 factors compared between the two stocks.
About Dr. Reddy’s Laboratories
Dr. Reddy’s Laboratories is an India-based pharmaceutical company that develops, manufactures and markets generic medicines, active pharmaceutical ingredients (APIs) and other healthcare products. Its portfolio includes branded and unbranded generics, biosimilars and select proprietary medicines across therapeutic areas such as oncology, gastroenterology, cardiovascular care and diabetes. Founded in 1984 by Kallam Anji Reddy, the company is headquartered in Hyderabad, India. It serves patients and customers in India and international markets, including the United States, Europe and countries in Russia and the Commonwealth of Independent States.
About Tvardi Therapeutics
Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and other serious diseases involving abnormal STAT3 signaling. STAT3 is a protein that can contribute to tumor growth, treatment resistance and immune suppression, making it a potential target for drug development. The company’s lead investigational product is TTI-101, an orally administered small-molecule inhibitor designed to block STAT3 activity. Tvardi is evaluating TTI-101 in clinical studies for solid tumors, including hepatocellular carcinoma and other advanced cancers.
Receive News & Ratings for Dr. Reddy's Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dr. Reddy's Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
